Eyenovia reports Q3 net loss $5.6M; Chairman Eshelman to step down

HYPERION DEFI, INC.

2021-Q3 EPS reported -$0.61 revenue$4,000,000

Net loss of $5.6M ($0.21 per share) vs $5.1M ($0.23) in Q3 2020; R&D $3.5M, G&A $2.4M.
Cash $21.4M at Sept 30; expects to fund MydCombi resubmission, MicroLine Phase 3, and manufacturing.
First patient enrolled in VISION-2 Phase 3 presbyopia trial; topline data expected mid-2022.
FDA issued Complete Response Letter reclassifying MydCombi as drug-device combo; expedited resubmission planned early 2022.
Chairman Fred Eshelman to resign by end of 2021; not due to disagreement; Board search to follow.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Fred Eshelman

Chairman of the Eyenovia Board

HYPD · HYPERION DEFI, INC.

Effective: 2021-12-31
Filed: November 10, 2021, 6:59 PM ET

Dr. Fred Eshelman, who has served as Chairman of the Eyenovia Board since 2014, will step down from the Board by the end of 2021 to pursue other professional interests.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Fred Eshelman resigned as Chairman of the Eyenovia Board at HYPERION DEFI, INC..

Action: resigned
Role: Chairman of the Eyenovia Board

Exact text from the filing

Dr. Fred Eshelman, who has served as Chairman of the Eyenovia Board since 2014, will step down from the Board by the end of 2021 to pursue other professional interests.

View on SEC.gov

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-21-136957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.